Experimental cell therapy aims to tame severe autoimmune diseases in kids
NCT ID NCT07439029
First seen Feb 28, 2026 · Last updated Jun 19, 2026 · Updated 18 times
Summary
This early study will test a new cell therapy called YTS109 in 12 children aged 5 to 17 with severe autoimmune diseases like lupus or scleroderma that haven't improved with standard treatments. The therapy is given as a single infusion, and the main goals are to check safety and find the right dose. Researchers will also look for signs that the treatment might help control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANCA ASSOCIATED VASCULITIS (AAV) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Hospital of Fudan University
Shanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
YTS109 cell therapy (a type of cell treatment given as a single infusion)
What this could lead to
If it works, this could point toward a new treatment option for children with severe autoimmune diseases that haven't responded to other therapies.
What could go wrong
This is a very early, small Phase 1 trial with only 12 children, so safety and effectiveness are not yet known. The treatment may cause serious side effects or not work at all.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.